Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)

STATUS

Recruiting
End date

Dec 14, 2023
participants needed

120
sponsor

Karyopharm Therapeutics Inc

Send

Updated on 7 October 2022

See if I qualify

systemic therapy

measurable disease

KRAS

pembrolizumab

docetaxel

cancer treatment

lung carcinoma

Summary

This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a checkpoint Inhibitor (CPI); or patients with normal HF, with colorectal cancer (CRC) who have had 1-3 prior lines (KRAS wild-type [WT]) or 1-2 prior lines (mutant KRAS) of treatment with no CPI; or patients with impaired HF, with any solid tumor, who have had at least 1 prior line of treatment.

The study will comprise 2 treatment periods (monotherapy and combination therapy).

The purposes of this study, during Monotherapy period, are: (1) to determine the relative bioavailability of the 100 milligrams (mg) (Tablet B) and 20 mg (Tablet A) tablets of selinexor at 100 mg once weekly (QW) dose in patients with normal hepatic function; and (2) to assess the PK of selinexor after a single dose of 40 mg (2 × 20 mg), among patients with moderate and severe hepatic impairment, relative to 100 mg (5 × 20 mg), among patients with normal hepatic function; and, during the Combination therapy period, to assess the preliminary anti-tumor activity of selinexor in combination with docetaxel in patients with NSCLC and with pembrolizumab or folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) in patients with CRC.

Description

Up to 120 patients will be enrolled, of which, 20 with normal HF will be able to continue from Monotherapy to Combination therapy and up to 106 patients with normal HF will receive combination therapy in total. Patients with impaired hepatic function can only participate in the Monotherapy part of the study.

Monotherapy Period:

For the Monotherapy Period of Study KCP-330-027, patients with normal hepatic function (n=20), will be allocated to one of two test formulation treatment arms, and will receive a cross-over once weekly oral dosing, with either 1x100 mg or 5x20 mg selinexor, for 2 weeks, and then will have the option to move on to the combination treatment part of the study. Patients with either moderately or severely impaired hepatic functions will be treated with 2x20 mg selinexor weekly (with an option to increase the dose every 3 weeks by 20 mg increments, up to 80 mg).

For the assessment of hepatic impairment, participants with any type of advanced or metastatic solid tumor who have moderate or severe hepatic impairment will be enrolled in Moderate Hepatic Impairment (MHI) (n=8) and Severe Hepatic Impairment (SHI) (n=6) arms, respectively and will be treated with 2 × 20 mg selinexor, weekly.

For Weeks 1 and 2, following an overnight fast of at least 10 hours, patients will be fed a standard low-fat meal 30 minutes prior to administration of once weekly selinexor. Patients should finish the meal in 30 minutes or less; however, selinexor dose should be administered 30 minutes after start of the meal.

Blood sampling for selinexor PK analyses will be collected ≤10 minutes (m) pre selinexor dose, and at 15m (±5m), 30m (±5m), 1 hour (h) (±5m), 1.5h (±5m), 2h (±10m), 3h (±10m), 4h (±10m), 5h (±10m), 6h (±10m), 8h (±20m), 10h (±20m; optional), 24h (±1h), 30h (±1h), and 48h (±2h) post selinexor dose. Practitioners must record the actual clock time for selinexor dose, and each sample drawn.

If a patient experiences emesis during the first 6 hours of the PK sampling, the PK results for that week will be excluded from the PK analysis dataset, and all testing timepoints must be re-collected during the following week (in this case, the same dosing formulation should be repeated on the following week, and other dosing formulation will be given the week after that).

Patients who will complete the Monotherapy Period will be reassessed for continuation to the Combination Therapy Period, as long as their Hepatic Function remains normal.

If a patient experiences significant toxicity related to selinexor and can't start the combination therapy immediately following monotherapy, dose interruption and weekly retesting are allowed for up to 21 days after the end of Monotherapy treatment visit. Patients requiring >21 days to recover from toxicities related to selinexor should be discussed with the Sponsor's Medical Monitor for documented approval to continue to the Combination Therapy Period. Reassessment may be extended then and following Medical Monitor approval up to 28 days.

Combination Therapy Period:

In the combination treatment period of the study, patients with normal hepatic functions will be allocated to one of 3 arms (with Arm C divided into 2 cohorts): Arm A (n= up to 40): Patients with NSCLC who have had up to 2 lines of prior systemic treatment with 1 line containing a CPI will receive 60 mg selinexor weekly, in combination with docetaxel 75 milligrams per meter square (mg/m^2) once every 3 weeks; Arm B (n= up to 40): Patients with CRC (KRAS WT) who have had up to 3 lines of prior systemic treatment or patients with CRC (KRAS mutant [KRAS Mut]) who have had up to 2 lines of prior systemic treatment, with no lines containing a checkpoint inhibitor (CPI) will receive 80 mg selinexor weekly, in combination with pembrolizumab 200 mg once every 3 weeks; Arm C (n<=26): Patients with CRC (regardless of KRAS status) who have had up to 2 lines of prior systemic treatment (regardless of CPI use) will receive either: (Cohort 1) selinexor 40 mg on days 1, 3, 15 and 18 in 28-day cycle + FOLFIRI; or (Cohort 2) selinexor 80 mg on days 1 and 15 in 28-day cycle + FOLFIRI.

Combination Therapy Period Patients will receive combination treatment until progressive disease (PD) or intolerable toxicity.

During both study periods, safety will be assessed through continuous reporting of adverse events (AEs), treatment-emergent adverse events (TEAEs), regularly scheduled clinical laboratory tests (hematologic and chemical), and physical examinations.

Tumor assessment will be performed with either computed tomography (CT) or magnetic resonance imaging (MRI) (CT with contrast preferred; for each patient, the imaging method should remain the same throughout the study).

Following treatment, patients will come in for a safety visit (approximately 30 days after the last dose of combination therapy) and will be followed for up to 2 years after that. Patients who discontinued due to PD will be followed for survival, and patients who discontinued for reasons other than PD will have tumor assessments until PD or until the start of new anti-neoplastic therapy, after which they will be followed for survival.

Details

Condition	Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
Treatment	docetaxel, Pembrolizumab, FOLFIRI, Selinexor, Selinexor 100 mg, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Clinical Study Identifier	NCT04256707
Sponsor	Karyopharm Therapeutics Inc
Last Modified on	7 October 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Common inclusion criteria for all patients
	Are greater than or equal to [≥] 18 years of age at the time of informed consent
	Have histologically confirmed solid tumor (any type of advanced or metastatic solid tumor for the Hepatic Impairment Arm of the Monotherapy Part), advanced or metastatic NSCLC or CRC and evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
	Willing to provide signed written informed consent in accordance with federal, local, and institutional guidelines and comply with all requirements of the study
	Female patient of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective (dual methods of) contraception throughout the study and for 4 months following the last dose of study drug; and male patients must use an effective barrier method of contraception throughout the study and for 4 months following the last dose of study drug if sexually active. Male patients must agree not to donate sperm during the study treatment period
	For the Monotherapy Part only (bioavailability/bioequivalence [BA/BE] and
	hepatic impairment [HI] arms)
	Have received at least 1 line of systemic anticancer treatment unless there is no first-line standard of care therapy or standard of care therapy is contraindicated adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy). Patients must have failed prior standard curative therapy for their disease, must be intolerant to or be ineligible for any potentially curative approved treatment, irrespective of line of therapy
	Must have either normal hepatic function, or moderate or severe hepatic impairment (as defined by the NCI organ dysfunction working group (NCI-ODWG) criteria
	S20-100 and S100-20 arms: normal hepatic function (total bilirubin and aspartate aminotransferase [AST] less than or equal to [≤] upper limit of normal [ULN])
	to 1.5 × ULN or AST > ULN) may be included if liver function tests are
	stable for the past 3 months and enrollment is approved in writing by the
	Sponsor's Medical Monitor
	MHI arm: ≥1 week of documented moderate hepatic impairment (total bilirubin >1.5-3 × ULN, any level of AST)
	SHI arm: ≥1 week of documented severe hepatic impairment (total bilirubin >3-10 × ULN, any level of AST)
	Note: Patients with mild hepatic dysfunction (total bilirubin greater than [>]
	Previous treatment lines (adjuvant or neoadjuvant therapy is not counted as one line
	of systemic therapy)
	Arm A: For patients with NSCLC, have received 1-2 prior lines of systemic
	anti-cancer treatment with 1 regimen including an anti-PD-1/L1 monoclonal
	antibody (mAb)
	Arm B: For patients with RAS mutant CRC, 1-2 prior lines of systemic treatments
	and no prior anti- programmed cell death protein 1/L1 monoclonal antibody
	(anti-PD-1/L1 mAb)
	For Combination Therapy Part only
	KRAS mutant (at least 50 percent [%] of patients): 1-2 prior lines of
	systemic treatments
	Arm C: For patients with CRC participating in the combination arm with FOLFIRI
	-2 prior lines of systemic therapy are allowed
	KRAS WT: have 1-3 prior lines of systemic treatments
	Arm B and C in CRC: patient with CRC who are not candidates for curative
	resection of metastatic lesions
	Arm A (combination with docetaxel): patients with NSCLC who are to receive
	Must have hepatic function as follows
	docetaxel and have bilirubin ≤ ULN, and AST and/or alanine transaminase (ALT) ≤
	5 x ULN
	Arm B and C: total bilirubin ≤ 1.5 × ULN and AST ≤ 2.5 x ULN, AST ≤ 2.5 x ULN
	for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which
	bilirubin must be ≤ 4 x ULN
Exclusion Criteria
	Inability or unwillingness to undergo a series of PK sampling
	Common exclusion criteria for all patients
	Have inadequate hematopoietic function defined as (without transfusion or growth
	factor support within 7 days prior to first dose)
	a. absolute neutrophil count (ANC) <1.5 × 109/liter (L); platelet count (PLT) <100 ×
	Prior exposure to a SINE compound or selinexor
	L; or hemoglobin (Hb) <9 gram per deciliter (g/dL)
	Have inadequate renal function defined as a calculated creatinine clearance (CrCl) of
	<20 mL/min using the formula of Cockcroft and Gault
	Have any other medical condition especially any gastrointestinal (GI) dysfunctions or
	GI disease that could interfere with the absorption of selinexor (e.g., inability to
	Palliative radiotherapy >14 days prior to the study is allowed
	swallow or retain oral medications, malabsorption syndrome, a history of GI surgery
	which may result in intestinal blind loop, significant gastroparesis, unresolved
	nausea, vomiting, or diarrhea [National Cancer Institute (NCI) Common Terminology
	Criteria for Adverse Events (CTCAE) Grade >1])
	Ongoing infection requiring parenteral antibiotics, antivirals, or antifungals on Day
	dosing
	Have an Eastern Cooperative Oncology Group (ECOG) performance status of
	Insufficient time since or not recovered from procedures or anti-cancer therapy
	defined as
	Not recovered from major surgery ≤21 days prior to Day 1 dosing. Minor
	procedures, such as biopsies, dental work, or placement of a port or intravenous
	(IV) line for infusion are permitted
	For Combination Therapy Part only
	Have ongoing clinically significant anti-cancer therapy-related toxicities CTCAE
	Grade >1. Patients with any of the following will not be excluded: immune
	checkpoint-related endocrinopathies that are well controlled with hormonal
	supplements, patients with electrolyte abnormalities that are well-managed with
	supplementation, patients with Grade 2 lymphopenia, or patients with alopecia of
	any grade. In specific cases, patients whose toxicity has stabilized or with
	Grade 2 non-hematologic toxicities can be allowed following documented approval
	by the Sponsor's Medical Monitor
	Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing
	Received investigational drugs in other clinical trials within 28 days, or 5
	half-lives of the investigational drug (whichever is shorter), prior to Cycle 1
	intended C1D1 of the Combination Therapy
	Day 1 (C1D1)
	Serious active psychiatric or active medical condition that could interfere with
	participation in the study or in the opinion of the Investigator would make study
	involvement unreasonably hazardous
	In the opinion of the Investigator, patients who are below their ideal body weight and
	would be unduly impacted by changes in their weight
	Known allergy to selinexor (all patients), docetaxel (NSCLC Arm A only), pembrolizumab
	(CRC arm B only), OR 5-FU, leucovorin, or irinotecan (CRC Arm C only)
	Female patients who are pregnant or breastfeeding. For Monotherapy Part only (BA/BE
	and HI arms)
	≥3 for patients to be enrolled into the S20-100 or S100-20 arms of the study
	≥4 for patients to be enrolled into the MHI and SHI arms of the study
	For MHI and SHI arms: ANC <1 × 109/L; PLT <75 × 109/L; or Hb <8 g/dL
	Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to Day 1 dosing OR
	strong CYP3A inducers ≤14 days prior to Day 1 dosing
	Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≥3 for Arms A
	and B and ECOG PS ≥2 for Arm C
	Arm B patients with CRC who are to receive pembrolizumab
	Had a diagnosis of immunodeficiency or are receiving systemic steroid therapy
	(>10 milligram per day [mg/day] of prednisone or equivalent) or any other form of
	immunosuppressive therapy
	Patients with controlled diabetes mellitus and patients with endocrinopathies on
	stable hormone replacement therapy, are eligible for the trial
	Have active autoimmune disease requiring systemic treatment during the past 2
	years. Type 1 diabetes mellitus, hypothyroidism only requiring hormone
	replacement skin disorders (such as vitiligo, psoriasis, or alopecia) not
	requiring systemic treatment, or conditions not expected to recur in the absence
	of an external trigger are permitted
	Note: The Investigator needs to evaluate the patient's medical history to confirm
	that they are eligible to receive the combination with pembrolizumab per these
	criteria
	For patients with CRC who have received live-attenuated vaccine against an
	infectious disease (e.g., nasal spray influenza vaccine) ≤14 days prior to the
	Arm C: Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Note: for
	patients who are initially enrolled onto the BA/BE arm in the monotherapy part and
	plan to switch to combination therapy after completing the planned dosing and PK
	sample collection, dose interruption between the Monotherapy Part and the Combination
	Therapy Part is allowed for recovery from AEs. Patients requiring >21 days to recover
	from toxicities related to selinexor should be discussed with the Sponsor's Medical
	Monitor for documented approval to continue to the Combination Therapy Part if
	inclusion/exclusion criteria are met. Experiencing PD during the Monotherapy Part does
	not constitute exclusion from the Combination Therapy Part

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)